· Diagramme
· Anti-emetic drugs
· Pro-emetic drugs
Drug |
Mechanism of anti-emesis |
Dexamethasone |
· Not well understood · For PONV prevention, not rescue · (onset 2 hours) · Receptor: transcription factor in cytosol; · Affects 25% of the genome |
5-HT3 antagonist |
e.g. ondansetron · Central: ↓afferent CTZ -> VC · Peripheral: ↓CNX afferent to CTZ via NTS |
DA2 antagonist: -Butyrophenone e.g. droperidol |
e.g. droperidol · ↓Afferent CTZ -> VC |
DA2 antagonist: -Phenothiazine |
e.g. prochlorperazine · ↓Afferent CTZ -> VC |
DA2 antagonist: -Benzamide |
Metoclopramide · Central: DA2i, 5HT3i (↓afferent from CTZ toVC) · Peripheral: DA2i, 5HT4a (↓afferent CNX to CTZ via NTS) · Anti-emetic and prokinetic |
Anti-histamine: first generation |
e.g. cyclizine · ↓Afferent CTZ to VC · ↓Afferent vestibular apparatus to CTZ · Strong anti-muscarinic · Weak anti-DA |
Anti-muscarinic |
e.g. atropine · mAChRi · Central: CTZ, vestibular · Peripheral: CNX afferent |
Propofol |
· Central 5HT3i · ↓Afferent from CTZ to VC |
Benzodiazepines |
e.g. midazolam · Positive allosteric modulator at GABA-A · ? ↓cortical afferent to CTZ |
Cannabinoids |
· Agonist at cannabinoid receptor in GIT · Esp cancer-associated nausea and vomiting |
NK-1 antagonist e.g. aprepitant |
e.g. aprepitant · Substance P antagonist at NK-1R · Peripheral: ↓CNX afferent to CTZ via NTS · Esp cancer N&V. Long duration. |
Opioids |
· Mu receptor agonist in CTZ |
Halogenated ethers |
· 5-HT agonist in CTZ |
Nitrous oxide |
· NMDA antagonism |
IV induction agents
|
· Ketamine: NMDA antagonism, 5HT reuptake inhibition, opioid agonism · Barbiturates · Etomdiate |
Ergometrine |
· 5-HT agonist in CTZ |
Feedback welcome at ketaminenightmares@gmail.com